Antiviral Drug Resistance: Clinical Consequences and Molecular Aspects

ABSTRACT

Antiviral drug resistance now poses a major problem for the management of patients with chronic hepatitis B. In theory, resistance may be prevented if a sufficiently potent antiviral drug, or combination of antiviral agents, is used that prevents viral replication and thereby the ongoing selection of hepatitis B virus quasispecies. Emergence of drug resistance in patients with hepatitis B generally results in progression of liver disease and in some cases, significant clinical deterioration if hepatic reserve is compromised. Currently, there are two major patterns of resistance mutations found in the viral reverse transcriptase (rt) that can be selected during monotherapy: (1) those that include the codon rtM204, which is part of the catalytic domain (YMDD) of the enzyme; (2) and those that do not include the codon. The rtM204I/V is selected by lamivudine and l-nucleosides. It is also part of the entecavir resistance profile and the tenofovir-lamivudine combination resistance profile. In contrast, resistance to adefovir is associated with mutations at rtN236T ± rtA181V. A reasonable clinical goal is to develop an overall strategy that prevents the selection of resistance. These strategies have yet to be optimized for hepatitis B, but may include multiple therapies such as immune-based therapies in combination with one or more nucleoside analogue treatments. Future treatment protocols can be modeled on the use of multiple agents comprising highly active anti-retroviral therapy regimens that have been developed for the successful management of patients infected with human immunodeficiency virus.

Hepatitis B virus - viral mutants - resistance - nucleoside analogues

REFERENCES

• 1 Durantel S, Werle B, Durantel D et al.. Different profiles of response to adefovir dipivoxial and factors that may influence response in patients with chronic hepatitis B.  Hepatology. 2004;  40(suppl 1) 654A
• 2 Locarnini S, Hatzakis A, Heathcote J et al.. Management of antiviral resistance in patients with chronic hepatitis B.  Antivir Ther. 2004;  9 679-693
• 3 Bowden S. Serological and molecular diagnosis.  Semin Liver Dis. 2006;  26 97-103
• 4 Chu C M, Liaw Y F. Hepatitis B virus-related cirrhosis: natural history and treatment.  Semin Liver Dis. 2006;  26 142-152
• 5 Zoulim F. In vitro models for studying hepatitis B virus drug resistance.  Semin Liver Dis. 2006;  26 171-180
• 6 Angus P, Vaughan R, Xiong S et al.. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase.  Gastroenterology. 2003;  125 292-297
• 7 Tenney D J, Levine S M, Rose R E et al.. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.  Antimicrob Agents Chemother. 2004;  48 3498-3507
• 8 Chin R, Shaw T, Torresi J et al.. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil.  Antimicrob Agents Chemother. 2001;  45 2495-2501
• 9 Delaney IV W E, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.  Antivir Chem Chemother. 2001;  12 1-35
• 10 Ono-Nita S K, Kato N, Shiratori Y, Carrilho F J, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.  Antimicrob Agents Chemother. 2002;  46 2602-2605
• 11 Levine S, Hernandez D, Yamanaka G et al.. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.  Antimicrob Agents Chemother. 2002;  46 2525-2532
• 12 Harrison T J. Hepatitis B virus: molecular virology and common mutants.  Semin Liver Dis. 2006;  26 87-96
• 13 Locarnini S, Mason W S. Cellular and virological mechanisms of HBV drug resistance.  J Hepatol. 2006;  44 422-431
• 14 Bartholomeusz A, Tehan B G, Chalmers D K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations.  Antivir Ther. 2004;  9 149-160
• 15 Bartholomew M M, Jansen R W, Jeffers L J et al.. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.  Lancet. 1997;  349 20-22
• 16 Allen M I, Deslauriers M, Andrews C W et al.. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.  Hepatology. 1998;  27 1670-1677
• 17 Xiong X, Yang H, Westland C E, Zou R, Gibbs C S. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.  Hepatology. 2000;  31 219-224
• 18 Delaney IV W E, Yang H, Westland C E et al.. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.  J Virol. 2003;  77 11833-11841
• 19 Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B.  J Med Virol. 1999;  59 270-276
• 20 Yeh C T, Chien R N, Chu C M, Liaw Y F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.  Hepatology. 2000;  31 1318-1326
• 21 Locarnini S, Shaw T, Sozzi T et al.. HBV mutants associated with clinical resistance to adefovir dipivoxil display only small decreases in antiviral sensitivity in vitro.  Hepatology. 2004;  40(suppl 1) 244A
• 22 Sheldon J, Camino N, Rodes B et al.. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.  Antivir Ther. 2005;  10 727-734
• 23 Feld J J, Heathcote E J. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment.  Semin Liver Dis.  2006;  26 116-129
• 24 Hadziyannis S J, Papatheodoridis G V. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.  Semin Liver Dis. 2006;  26 130-141
• 25 Leung N W, Lai C L, Chang T T et al.. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology. 2001;  33 1527-1532
• 26 Papatheodoridis G V, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis S J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.  Hepatology. 2002;  36 219-226
• 27 Liaw Y F, Chien R N, Yeh C T, Tsai S L, Chu C M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.  Hepatology. 1999;  30 567-572
• 28 Lok A S, Lai C L, Leung N et al.. Long-term safety of lamivudine treatment in patients with chronic hepatitis B.  Gastroenterology. 2003;  125 1714-1722
• 29 Dienstag J L, Goldin R D, Heathcote E J et al.. Histological outcome during long-term lamivudine therapy.  Gastroenterology. 2003;  124 105-117
• 30 Lin C L, Tsai S L, Lee T H, Chien R N, Liao S K, Liaw Y F. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.  Gut. 2005;  54 152-161
• 31 Liaw Y F, Sung J J, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
• 32 Fung S K, Andreone P, Han S H et al.. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.  J Hepatol. 2005;  43 937-943
• 33 Ayres A, Bartholomeusz A, Lau G, Lam K C, Lee J Y, Locarnini S. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure.  J Clin Virol. 2003;  27 111-116
• 34 Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B.  Semin Liver Dis. 2003;  23 69-79
• 35 Bartholomeusz A, Locarnini S, Ayres A et al.. Mechanistic basis for hepatitis B virus resistance to acyclic nucleoside phosphonate analogues, adefovir and tenofovir.  Hepatology. 2005;  42(suppl 1) 594A
• 36 Ono S K, Kato N, Shiratori Y et al.. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.  J Clin Invest. 2001;  107 449-455
• 37 Bock C T, Tillmann H L, Torresi J et al.. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.  Gastroenterology. 2002;  122 264-273
• 38 Liaw Y F, Chien R N, Yeh C T. No benefit to continue lamivudine therapy after emergence of YMDD mutations.  Antivir Ther. 2004;  9 257-262
• 39 Wong V W, Chan H L, Wong M L, Tam J S, Leung N W. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.  Aliment Pharmacol Ther. 2004;  19 323-329
• 40 Angus P, Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!.  Antivir Ther. 2004;  9 145-148
• 41 Ono-Nita S K, Kato N, Shiratori Y et al.. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.  J Clin Invest. 1999;  103 1635-1640
• 42 Perrillo R, Hann H W, Mutimer D et al.. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.  Gastroenterology. 2004;  126 81-90
• 43 Peters M G, Hann H W, Martin P et al.. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.  Gastroenterology. 2004;  126 91-101
• 44 Lee C H, Yeon J E, Hong S P et al.. More frequent and earlier emergence of adefovir (ADV) resistance mutations in lamivudine resistant patients treated with ADV compared to previously reported nucleoside-treatment naive patients.  Hepatology. 2005;  42 593A
• 45 Fung S K, Lok A S. Management of hepatitis B patients with antiviral resistance.  Antivir Ther. 2004;  9 1013-1026
• 46 Suzuki F, Tsubota A, Akuta N et al.. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.  J Gastroenterol. 2002;  37 922-927
• 47 Danalioglu A, Kaymakoglu S, Cakaloglu Y et al.. Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.  Int J Clin Pract. 2004;  58 659-661